AI assistant
Evotec SE — M&A Activity 2012
Oct 1, 2012
151_rns_2012-10-01_483a156c-cb4c-494e-b023-c7b1c0ddb616.html
M&A Activity
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 1 October 2012 10:35
Evotec and Bayer enter into multi-target alliance to fight endometriosis
Evotec AG / Key word(s): Alliance
01.10.2012 10:35
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany - Evotec AG (Frankfurt Stock Exchange, Prime Standard,
ISIN: DE 000 566480 9, WKN 566480) that Evotec and Bayer Pharma AG have
entered into a five-year, multi-target collaboration with the goal of
developing three clinical candidates for the treatment of endometriosis.
Both parties will contribute innovative drug targets and high quality
technology infrastructures and will share the responsibility for early
research and pre-clinical characterisation of potential clinical candidates
in the disease area of endometriosis.
Bayer will be responsible for any subsequent clinical development and
commercialisation. Evotec will receive EUR 12 million as an upfront
payment. Evotec may also receive additional pre-clinical, clinical and
sales milestones of potentially up to approximately Euro 580 million, plus
potential royalties of up to low double digit percent of net sales,
depending on which party brought the compound to the collaboration and the
successful development and approval of potential drug candidates.
Contact: Dr Mario Polywka, Chief Operating Officer, Evotec AG, Manfred
Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560
81-255, [email protected]
01.10.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart
End of Announcement DGAP News-Service